Softwr

Healthcare · head to head

Therapixel vs UpToDate

Therapixel logo

Therapixel

Healthcare

French mammography AI with FDA clearances for 2D and tomosynthesis breast screening

From
On request
Rated
-
Full reviewWebsite
UpToDate logo

UpToDate

Healthcare

Evidence-based clinical decision support for healthcare providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Therapixel european and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.; UpToDate upToDate does not publish subscription prices; the vendor (Wolters Kluwer) sorts buyers into separate individual, clinic-wide, and institutional subscription tracks and requires contacting the organization through its subscription-payment-options page rather than showing a rate for any of them.
  • They diverge on capability: Therapixel covers MammoScreen 2D, UpToDate covers Clinical Evidence.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Therapixel and UpToDate actually diverge.

Attributes where Therapixel and UpToDate differ
AttributeTherapixelUpToDate
Pricing modelquotesubscription
PlatformsWebWeb, Mobile
FoundedUnknown1992

Identical on both: starting price (On request), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Therapixel

  • MammoScreen 2D
  • MammoScreen DBT
  • One to ten suspicion score
  • Summary report
  • Workstation and PACS delivery
  • Reading workflow configurations

Only in UpToDate

  • Clinical Evidence
  • Drug Information
  • Calculators
  • Medical Images
  • Videos
  • CME Credits
  • EHR Systems
  • Mobile

What people use each for

The jobs each tool is most often brought in to do.

Therapixel

  • A European breast screening programme running mandatory double reading that wants to evaluate AI as a concurrent or second reader within what national guidance permitsnot UpToDate
  • An American breast centre that has moved to tomosynthesis and needs reading support on DBT specifically, which Therapixel holds a clearance fornot UpToDate
  • A screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own thresholdnot UpToDate
  • A radiology group evaluating multiple mammography AI vendors head to head on their own historic case set before committingnot UpToDate

UpToDate

  • Patient Carenot Therapixel
  • Medical Recordsnot Therapixel
  • Practice Managementnot Therapixel
  • Telehealthnot Therapixel

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Therapixel

  • European and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • MammoScreen does mammography only, so a hospital wanting AI across head CT, chest and breast needs several vendors and several PACS integrations, or an orchestration layer bought from someone else.
  • Therapixel is a small French company competing against Hologic and iCAD, which have incumbency inside the mammography reading workstation, so integration into an American breast centre is more work than it is for the workstation vendor own AI.
  • Detection performance is sensitive to the mammography unit vendor and acquisition protocol, so published results do not transfer between estates and each site needs local validation it must fund itself.
  • Whether AI can substitute for one of two human readers is a national workforce and liability question, not a product capability, so the labour saving that justifies the purchase in one country is not permitted in another.

UpToDate

  • UpToDate does not publish subscription prices; the vendor (Wolters Kluwer) sorts buyers into separate individual, clinic-wide, and institutional subscription tracks and requires contacting the organization through its subscription-payment-options page rather than showing a rate for any of them.

Pricing, plan by plan

Therapixel

On request
  • MammoScreen$undefined/year
    • Priced per examination or by annual screening volume
    • 2D and tomosynthesis licensed by the versions cleared for each
    • Cloud or on premises deployment quoted differently

UpToDate

On request

No published plan breakdown. See the UpToDate review.

Which should you pick?

Choose Therapixel if

  • You need mammoscreen 2d.
  • You also want mammoscreen dbt.
Therapixel review

Choose UpToDate if

  • You need clinical evidence.
  • You work on Web, Mobile.
  • You also want drug information.
UpToDate review

Questions people ask

Is Therapixel or UpToDate better?
Neither clearly leads. Therapixel starts at On request and UpToDate at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Therapixel or UpToDate?
Therapixel starts at On request and UpToDate at On request.
Does Therapixel or UpToDate run on more platforms?
Therapixel runs on Web. UpToDate runs on Web, Mobile.
What is Therapixel best used for?
Therapixel is most often used for a european breast screening programme running mandatory double reading that wants to evaluate ai as a concurrent or second reader within what national guidance permits, an american breast centre that has moved to tomosynthesis and needs reading support on dbt specifically, which therapixel holds a clearance for, a screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own threshold, a radiology group evaluating multiple mammography ai vendors head to head on their own historic case set before committing. Of those, a european breast screening programme running mandatory double reading that wants to evaluate ai as a concurrent or second reader within what national guidance permits and an american breast centre that has moved to tomosynthesis and needs reading support on dbt specifically, which therapixel holds a clearance for are not what UpToDate is typically brought in for.
What can Therapixel do that UpToDate cannot?
Therapixel covers MammoScreen 2D, MammoScreen DBT, One to ten suspicion score, Summary report. UpToDate covers Clinical Evidence, Drug Information, Calculators, Medical Images.

Answered from the vendors’ own pages

Therapixel: Is MammoScreen FDA cleared?

Yes. It holds 510(k) clearance K192854 for two dimensional mammography from July 2020, a November 2021 clearance for digital breast tomosynthesis, and two further clearances in October 2024 for later versions.

Therapixel: Is it CE marked?

Yes, but European buyers should ask specifically for the current certificate under the Medical Device Regulation and its expiry date, because this class of diagnostic AI moved to a higher classification under MDR.

Therapixel: What does the one to ten score mean?

It is a graded suspicion score per finding and per study, designed to be integrated alongside a radiologist BI-RADS assessment rather than treated as a positive or negative result.

Therapixel: Does it cover anything besides mammography?

No. It is a mammography product only, including tomosynthesis. Other body regions need a different vendor.

Share

Related pages

More on Therapixel

More on UpToDate

Keep looking

Other head to heads